Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 100,951 |
|
|||||
| News | - | ||||||
| Day High | 18.82 | Low High |
|||||
| Day Low | 18.41 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Kura Oncology Inc | KURA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.05 | -0.27% | 18.68 | 11:16:06 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 18.75 | 18.41 | 18.82 | 18.73 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,188 | 100,951 | $ 18.66 | $ 1,883,330 | - | 7.41 - 24.17 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:16:50 | 23 | $ 18.67 | USD |
Kura Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.43B | 76.14M | - | 0 | -152.63M | -2.00 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Kura Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KURA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 18.80 | 19.27 | 16.79 | 18.00 | 1,366,250 | -0.12 | -0.64% |
| 1 Month | 20.44 | 21.89 | 16.79 | 19.33 | 865,011 | -1.76 | -8.61% |
| 3 Months | 21.12 | 24.17 | 16.79 | 20.72 | 974,406 | -2.44 | -11.55% |
| 6 Months | 7.67 | 24.17 | 7.41 | 16.82 | 1,223,803 | 11.01 | 143.55% |
| 1 Year | 10.89 | 24.17 | 7.41 | 14.42 | 992,173 | 7.79 | 71.53% |
| 3 Years | 28.24 | 28.81 | 7.41 | 15.12 | 835,706 | -9.56 | -33.85% |
| 5 Years | 15.59 | 42.82 | 6.34 | 17.63 | 706,542 | 3.09 | 19.82% |
Kura Oncology Description
| Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. |
